SCHEMBL17500294

SCHEMBL17500294

COC(=O)c1ccc(Cn2c3c(c4ccccc42)C2CN(C3)CN(C)C2=O)cc1

nearest known ligand 0.80

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 18/20 0.80
▸ HDAC2 Q92769 15/20 0.80
▸ HDAC8 Q9BY41 15/20 0.80
▸ HDAC3 O15379 1/20 0.58
▸ HDAC4 P56524 1/20 0.58
▸ HDAC1 Q13547 1/20 0.58
▸ HDAC7 Q8WUI4 1/20 0.58
▸ HDAC10 Q969S8 1/20 0.58
▸ HDAC11 Q96DB2 1/20 0.58
▸ HDAC5 Q9UQL6 1/20 0.58
▸ NCOR2 Q9Y618 1/20 0.58
▸ CNR2 P34972 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19161244 1.00 HDAC6 (0.80) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19161727 0.89 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520534 0.89 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19138927 0.89 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520641 0.89 HDAC6 (0.85) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL20629459 0.86 HDAC6 (0.78) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL24012098 0.81 HDAC6 (0.85) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520642 0.80 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19161250 0.79 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19139006 0.79 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 — — EP disclosed
US-10106540-B2 HDAC6 inhibitors and their uses UNIVERSITÄT REGENSBURG (DE) 2018-10-23 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
EP-3177621-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universität Regensburg (DE) 2017-06-14 — — EP disclosed
WO-2016020369-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2016-02-11 — — WO disclosed
WO-2016020369-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2016-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 10/4885
US-10106540-B2 HDAC6 inhibitors and their uses HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback